AU2013204153A1 - Treatment of TNFalpha related disorders - Google Patents

Treatment of TNFalpha related disorders

Info

Publication number
AU2013204153A1
AU2013204153A1 AU2013204153A AU2013204153A AU2013204153A1 AU 2013204153 A1 AU2013204153 A1 AU 2013204153A1 AU 2013204153 A AU2013204153 A AU 2013204153A AU 2013204153 A AU2013204153 A AU 2013204153A AU 2013204153 A1 AU2013204153 A1 AU 2013204153A1
Authority
AU
Australia
Prior art keywords
related disorders
treatment
tnfalpha
tnfa
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013204153A
Inventor
Murtaza Anwar
Subhashis Banerjee
William T. Barchuk
Elliot Keith Chartash
Steven Fischkoff
Rebecca S. Hoffman
Jochen G. Salfeld
Clive E. Spiegler
Lori K. Taylor
Daniel Edward Tracey
Philip Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotechnology Ltd
Original Assignee
AbbVie Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012203853A external-priority patent/AU2012203853B2/en
Application filed by AbbVie Biotechnology Ltd filed Critical AbbVie Biotechnology Ltd
Priority to AU2013204153A priority Critical patent/AU2013204153A1/en
Publication of AU2013204153A1 publication Critical patent/AU2013204153A1/en
Assigned to ABBVIE BIOTECHNOLOGY LTD reassignment ABBVIE BIOTECHNOLOGY LTD Amend patent request/document other than specification (104) Assignors: ABBOTT BIOTECHNOLOGY LTD.
Abandoned legal-status Critical Current

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Treatment of TNFa related disorders Methods of treating TNFa related disorders comprising administering TNFa inhibitors, including TNFa antibodies are described.
AU2013204153A 2002-07-19 2013-04-12 Treatment of TNFalpha related disorders Abandoned AU2013204153A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013204153A AU2013204153A1 (en) 2002-07-19 2013-04-12 Treatment of TNFalpha related disorders

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US60/397,275 2002-07-19
US60/411,081 2002-09-16
US60/417,490 2002-10-10
US60/455,777 2003-03-18
AU2012203853A AU2012203853B2 (en) 2002-07-19 2012-06-29 Treatment of TNFalpha related disorders
AU2013204153A AU2013204153A1 (en) 2002-07-19 2013-04-12 Treatment of TNFalpha related disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2012203853A Division AU2012203853B2 (en) 2002-07-19 2012-06-29 Treatment of TNFalpha related disorders

Publications (1)

Publication Number Publication Date
AU2013204153A1 true AU2013204153A1 (en) 2013-05-02

Family

ID=48446904

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013204153A Abandoned AU2013204153A1 (en) 2002-07-19 2013-04-12 Treatment of TNFalpha related disorders
AU2013204147A Expired AU2013204147B2 (en) 2002-07-19 2013-04-12 Treatment of TNFalpha related disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2013204147A Expired AU2013204147B2 (en) 2002-07-19 2013-04-12 Treatment of TNFalpha related disorders

Country Status (1)

Country Link
AU (2) AU2013204153A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα

Also Published As

Publication number Publication date
AU2013204147B2 (en) 2015-09-03
AU2013204147A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
MY151032A (en) Treatment of tnf? related disorders
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
MY180762A (en) Combination therapy comprising glucose reabsorption inhibitors and ppar modulators.
WO2003101444A8 (en) Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
MY140767A (en) Compounds, methods and compositions
NO20053042L (en) Use of spongosine (2-methoxyadenosine) for the treatment of pain, especially hyperalgesia.
WO2003103575A3 (en) Compounds, compositions, and methods
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
ATE515514T1 (en) USES OF MAMMAL CYTOKINE IL-23 ; RELATED REAGENTS
AU2000233235A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
MY148432A (en) Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators.
MY140169A (en) Compounds, compositions, and methods
NO20052267L (en) Compounds, Preparations and Methods
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
WO2005053609A3 (en) Methods of nad+-dependent deacetylase inhibitors
TW200508233A (en) Chk-1 inhibitors
TW200509896A (en) Analeptic and drug combinations
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
AU2003252025A1 (en) Compounds, compositions, and methods
HK1029944A1 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
WO2003105753A3 (en) Targeted enzymes and methods of making and using targeted enzymes.
WO2004030634A3 (en) Therapeutic compositions
AU2003223538A1 (en) Methods for the treatment of cancer
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application